WARF: P96091US

Methods and Compositions for Treating Animals to Maintain or Enhance Bone Mineral Content


Mark Cook, Michael Pariza

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a method of treating animals to maintain or increase mineral content in bone.
OVERVIEWMany animals, including humans, lose bone minerals as they age or if they are afflicted with certain diseases. Loss of calcium in bone can cause osteoporosis. However, most of the current compounds known to maintain or increase bone calcium are potent biological agents with significant side effects.
THE INVENTIONUW–Madison researchers have developed a method of treating an animal to maintain or enhance the mineral content of the bones of the animal. The method consists of administering to the animal a safe and effective amount of conjugated linoleic acid (CLA).
  • Prevention or treatment of osteoporosis
  • Capable of maintaining or enhancing the mineral content of skeletal bones in animals
For More Information About the Inventors
Contact Information
For current licensing status, please contact Emily Bauer at or (608) 262-8638.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.